Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
US Urges Iran to Transfer Enriched Uranium as Ceasefire Talks Continue 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
The four types of dementia most people don’t know exist 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
U.S. Criticizes Airspace Denials to Taiwan President as China Influence Grows 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Trump Extends Iran Ceasefire Amid Ongoing Negotiations and Pakistan’s Request 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Iran Open to U.S. Talks in Pakistan if Pressure Policy Ends, Official Says 
Trump Administration Proposes New Rule to Limit Joint Employer Liability 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
U.S. Health Secretary Robert F. Kennedy Jr. told lawmakers this week that he is open to sharing details about David Geier’s contract with the Department of Health and Human Services (HHS), signaling growing scrutiny over the controversial appointment. During a Senate Finance Committee hearing, Kennedy stated that the contract could be provided to senators before the end of the week, offering what may become the first clear explanation of Geier’s responsibilities within the agency.
David Geier, known for his long-standing anti-vaccine activism, is currently working as a contractor tied to the Centers for Disease Control and Prevention (CDC). According to federal records, he is listed as a senior data analyst within the HHS system. His involvement has raised concerns among lawmakers and public health experts, particularly given his history of promoting debunked claims linking vaccines to autism.
Senator Ben Ray Luján of New Mexico pressed Kennedy on whether the administration would also release the protocols guiding Geier’s work. Kennedy responded that such protocols are not yet in place but promised they would be shared once the vaccine safety review is completed. Kennedy has previously indicated that Geier is leading a review of CDC vaccine data, a move that has sparked debate due to Geier’s controversial background.
Geier’s past actions have added to the concern. He was previously fined in Maryland for practicing medicine without a license and for administering unsafe treatments to children with autism. Critics argue that his involvement in federal health initiatives could undermine public trust in vaccine safety.
The situation highlights ongoing tensions around vaccine policy, public health transparency, and the role of individuals with disputed scientific views in government positions. As pressure builds, the release of Geier’s HHS contract could play a key role in shaping public and political response to the administration’s handling of vaccine-related issues.
